FDA leaders have signaled a shift in evidentiary standards under Section 505(d) of the Federal Food, Drug, and Cosmetic Act, enabling approval based on one adequate and well-controlled clinical investigation plus confirmatory evidence rather than two independent pivotal studies. The new approach emphasizes trial quality and scientific justification while preserving agency discretion to evaluate development programs on their merits.

Adial had historically planned two costly Phase 3 trials for its lead candidate AD04, targeting Alcohol Use Disorder in genetically defined heavy drinkers. Under the one-trial framework, the company could slash Phase 3 expenditures, improve capital efficiency and shorten development timelines without compromising regulatory standards.

AD04 is a genetically targeted serotonin-3 receptor antagonist currently entering late-stage development. Adial plans to engage closely with the FDA to define an evidentiary strategy that aligns with the new policy, aiming to accelerate the New Drug Application submission and potentially expand indications to other addictive disorders.

While the policy shift offers strategic and economic upside, Adial must still demonstrate substantial evidence of effectiveness and meet all agency requirements. The company’s future milestones include finalizing trial designs, securing funding for Phase 3, and advancing discussions on confirmatory endpoints.